OBJECTIVE Pancreatic cancer (PC) is the fourth leading cause of cancer death due to insufficient diagnostic methods in early stage of PC. Growing evidence has shown that long intergenic non-coding RNAs (LINCRNAs) is a biomarker of the early-stage of PC. However, the expression level and diagnostic value of LINC00162 remains unclear. METHODS LINC00162 expression was detected in peripheral blood samples from 155 subjects (52 healthy controls, 52 benign pancreatic disease (BPD) persons and 51 PC patients) by quantitative reverse transcription real-time polymerase chain reaction. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic value of LINC00162, carcinoembryonic antigen (CEA) and cancer antigen 199 (CA199). RESULTS Our data indicated that the LINC00162 expression was upregulated in PC patients compared with healthy controls and BPD (all P<0.001). Furthermore, PC patients with advanced pathological grades, positive lymph node metastasis and positive distant metastasis showed higher LINC00162 levels (all P<0.001). In addition, the area under the ROC curve (AUC) found that the LINC00162 had higher diagnostic ability than CEA and CA199 in distinguishing the early-stage PC patients (AUC: LINC00162 versus(vs) CEA vs CA199=0.932 vs 0.669 vs 0.725). CONCLUSION In summary, the LINC00162 may be a noninvasive and efficient marker for identifying patients with the early-stage PC. Further validation studies with a large number of patients and long-term follow-up patients are needed to confirm the potential diagnostic value and clinical utility of LINC00162 in patients with PC.

中文翻译：

---

长基因间非编码 00162 作为早期胰腺癌的诊断生物标志物。


目的 胰腺癌（PC）是癌症死亡的第四大原因，由于早期诊断方法不足。越来越多的证据表明，长基因间非编码 RNA (LINCRNA) 是 PC 早期的生物标志物。然而，LINC00162的表达水平和诊断价值仍不清楚。方法 通过定量逆转录实时聚合酶链反应检测 155 名受试者（52 名健康对照、52 名良性胰腺疾病（BPD）患者和 51 名 PC 患者）的外周血样本中 LINC00162 的表达。采用受试者工作特征（ROC）分析评估LINC00162、癌胚抗原（CEA）和癌抗原199（CA199）的诊断价值。结果我们的数据表明，与健康对照和 BPD 相比，PC 患者中的 LINC00162 表达上调（均 P<0.001）。此外，病理分级晚期、淋巴结转移阳性和远处转移阳性的PC患者的LINC00162水平较高（均P<0.001）。此外，ROC曲线下面积（AUC）发现LINC00162在区分早期PC患者方面比CEA和CA199具有更高的诊断能力（AUC：LINC00162 vs（vs）CEA vs CA199=0.932 vs 0.669 vs 0.725） 。结论 总之，LINC00162 可能是识别早期 PC 患者的无创且有效的标记物。需要对大量患者和长期随访患者进行进一步的验证研究，以确认 LINC00162 对 PC 患者的潜在诊断价值和临床效用。